

Patient Information			Prescriber Information	
Patient Name:	DOB:		Prescriber's Name:	
Address:			NPI#:	
City:	State:	Zip:	DEA#:	License#:
Phone:	Alternate Phone:	SSN:	Address:	
Height:	Weight:	Allergies:	Phone:	Fax:
Emergency Contact:	Phone:		Contact Person:	

Is the patient pregnant, planning a pregnancy or nursing:    Yes    No                      Does the patient need interpreter services:    Yes    No

Documentation (Required)		
Insurance Card (ID & Group #)	Current Medications	History/Progress Notes

Labs Needed Prior to Initiation			
Tuberculosis	Hepatitis B antigen and antibody	CBC with diff	CMP

Diagnosis			
<b>ICD-10 Codes:</b>	K50 Crohn's Disease	K51.9 Ulcerative Colitis, unspecified	K50 Irritable Bowel Syndrome w/diarrhea
Other: _____			

Medication	Dose	Directions for Use	Qty	Refills
<b>CIMZIA®</b> (certolizumab pegol)	200 mg/mL x 2	<b>Initial:</b> Inject 400 mg subq at weeks 0, 2, and 4 <b>Maintenance:</b> Inject 400 mg subq every 4 weeks		
<b>ENTYVIO®</b> (vedolizumab)	300 mg vial	<b>Initial:</b> Infuse 300 mg IV at week 0, 2, and 6 <b>Maintenance:</b> Infuse 300 mg IV every 8 weeks Inject 108 mg subq every 2 weeks Other: _____		
<b>ENTYVIO® Pen</b> (vedolizumab)	108 mg/0.68 mL			
<b>HUMIRA®</b> Crohn's/UC Starter Kit (adalimumab)	Starter kit	<b>Initial:</b> Inject 160 mg subq over 1-2 days, 80 mg 2 weeks later on day 15 <b>Maintenance:</b> Inject 40 mg subq every other week beginning day 29 Other: _____	1 kit	
<b>HUMIRA®</b> (adalimumab)	40 mg/0.4 mL			
<b>PFS</b>	40 mg/0.8 mL			
<b>Pen</b>	80 mg/0.8 mL			
<b>Other biosimilar:</b> _____				
<b>REMICADE®</b> (infliximab)	100 mg/mL	<b>Initial:</b> Infuse 5 mg/kg = _____ mg IV at weeks 0, 2, and 6 <b>Maintenance:</b> 5 mg/kg = _____ mg IV every 8 weeks Other: _____		
<b>Other biosimilar:</b> _____				
<b>SKYRIZI®</b> (risankizumab)	600 mg vial	<b>Initial:</b> Infuse 600 mg IV at weeks 0, 4 and 8 Infuse 1200 mg IV at weeks 0, 4 and 8 <b>Maintenance:</b> Inject 180 mg subq at week 12 and every 8 weeks Inject 360 mg subq at week 12 and every 8 weeks		
<b>SKYRIZI®</b> On-body (risankizumab)	180 mg 360 mg			
<b>SIMPONI®</b> (golimumab)	100 mg/mL	<b>Initial:</b> Inject 200 mg subq at week 0 Inject 100 mg subq at week 2 <b>Maintenance:</b> Inject 100 mg subq every 4 weeks		
<b>PFS</b>				
<b>Pen</b>				

Medication	Dose	Directions for Use	Qty	Refills
<b>STELARA®</b> (ustekinumab) <b>STELARA®</b> (ustekinumab) PFS Pen Other biosimilar: _____	130 mg/26 mL vial  90 mg/mL	<b>Initial:</b> </= 55 kg: Infuse 260 mg IV one time > 55-85 kg: Infuse 390 mg IV one time > 85 kg: Infuse 520 mg IV one time <b>Maintenance:</b> Inject 90 mg subq every 8 weeks		
<b>TREMFYA®</b> (guselkumab) <b>TREMFYA®</b> (guselkumab) PFS Pen	200 mg/20 mL vial  100 mg/mL	<b>Initial:</b> Infuse 200 mg IV on week 0, 4, and 8 Inject 400 mg subq (2 consecutive injections) on week 0, 4, and 8 (option for Crohn's only) <b>Maintenance:</b> Inject 100 mg subq every 8 weeks from week 16 OR: Inject 200 mg subq every 4 weeks from week 12		
<b>XIFAXAN®</b> (rifamixin)	550 mg tablet	Take one tablet by mouth three times per day x 14 days Other: _____		

By signing this form I authorize Aleracare and its representatives to act as my agent in order to initiate and execute the insurance prior authorization process and, in doing so release clinical information via phone to the appropriate third party payer.

 \_\_\_\_\_  
**Prescriber's Signature**

 \_\_\_\_\_  
**Date**